bladder cancer trial

A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) With Mitomycin C (Synergo® RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC) Bacillus Calmette-Guérin (BCG)-Unresponsive Patients With or Without Papillary NMIBC

Synergo® RITE + MMC is an investigational combination product and is undergoing a clinical trial in the USA.

This study will determine whether Synergo® RITE + MMC treatment is efficacious as second-line therapy for CIS NMIBC BCG-unresponsive patients with or without papillary NMIBC, through examination of the complete response rate (CRR) and disease-free duration for complete responders. The study will also explore progression-free survival time, bladder preservation rate, and overall survival time.

For more information and recruiting sites, please refer to clinicaltrials.gov.

© 2018 by MEL Medical Enterprises Ltd.

6 Odem st., Petah Tikva ISRAEL

Tel: +97239244830 Fax: +97239245340

Email: info@synergo-medical.com